Melissa A. Troester

Professor

University of North Carolina at Chapel Hill
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (49)

Year:

2026

Purpose Inflammatory breast cancer (IBC) has been hypothesized to represent a distinct molecular subtype. However, few IBC-specific gene expression patterns have been identified, and previous genomic studies of IBC have been small with limited information on social determinants. Methods We identified 153 IBC cases in the Carolina Breast Cancer Study (total N = 4,739). RNA expression was measured on the NanoString platform ( N = 74 IBC, 2,696 non-IBC) and used to determine molecular subtypes, including PAM50, immune, homologous recombination deficiency (HRD), and P53 status. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) of associations between IBC and patient demographic, molecular, and social characteristics using logistic regression, and compared differences in gene expression using ANOVA. Results Women with IBC were associated with Black and under 50 compared to non-IBC. IBC was associated with rural address (OR = 1.53) and poverty (OR = 1.61). Molecularly, IBC was associated with HER2-enriched (OR = 6.14), Luminal B (OR = 2.90), P53 Mutant-like (OR = 1.79), and high HRD (OR = 1.90). Neither adiposity nor immune subtype was significantly associated with IBC. Only six of 219 genes measured were significantly differentially expressed between IBC and non-IBC, including HER2-related (ERBB2, FGFR4, GRB7) and P53-related genes (BTG2, LOC400043, MAP2K4). Conclusion Although not associated with immune subtypes, IBC showed differences in HER2 and P53 pathways. The association of IBC with rurality and poverty underscores the importance of health care access for timely diagnosis and treatment of IBC.

Year:

2026

Background: Treatment approaches differ for isolated in-breast tumor recurrence (representing treatment failure) and new primary breast tumors (representing high etiologic risk). However, methods for distinguishing recurrences from second primaries (based on radiographic and histologic criteria) are subject to error. Gold-standard genomic datasets for assessing classification accuracy have been lacking. Methods: To identify the scope of misclassification, we performed DNA sequencing of 1,200 genes in 108 participants with synchronous or metachronous second breast cancer in the Carolina Breast Cancer Study (CBCS3). DNA sequencing data included 87 second tumors and 42 paired first and second breast cancers in the same patient (14 contralateral and 28 ipsilateral). Recurrence status was classified based on mutations and copy number, accounting for site-specific mutation probabilities. DNA-based recurrence versus second primary classifications were compared with clinical and Surveillance, Epidemiology and End Results (SEER) classifications based on laterality, histology, quadrant, and latency. Results: Twenty-two of 28 ipsilateral tumor pairs (79%) shared at least one mutation and were classified as recurrences. Pathologist classifications of ipsilateral second tumors were 79% accurate [95% confidence interval (CI), 60%–90%) with higher sensitivity (95%, 95% CI = CI, 78%–99%) and lower specificity (17%, 95% CI, 3%–56%). SEER classifications were 82% accurate (95% CI, 64%–92%) with lower sensitivity (77%, 95% CI, 57%–90%) and higher specificity (100%, 95% CI, 61%–100%). Conclusions: Although most genomically defined recurrences are captured by clinical recurrence definitions, new primaries are frequently misclassified. Impact: Given overtreatment harms, genomic methods may support treatment de-escalation for second breast cancers.

Year:

2026

Cancer genomics consortia have identified somatic drivers of breast cancer subtypes. However, these studies have predominantly included older, non-Black women, and the related socioeconomic status (SES) data are limited. Increased representation and depth of social data are crucial for understanding how health inequity is intertwined with somatic landscapes. Here, we conducted targeted sequencing on primary tumors from the Carolina Breast Cancer Study (N = 357; 52% Black; 47% <50) and compared the results with The Cancer Genome Atlas (N = 948; 18% Black; 27% <50). Race (Black vs. non-Black), age, and SES were evaluated in association with mutations, copy number alterations, and aneuploidy using generalized linear models. Pathway dysfunction was also assessed by aggregating mutation and copy number alterations. Adjusting for age, Black participants (N = 350) were significantly more likely to have TP53 and FAT1 mutations and less likely to have PIK3CA, CDH1, DDR2, and GATA3 mutations than non-Black participants. Younger participants had more GATA3 alterations and fewer KMT2C, PTEN, MAP3K1, and CDH1 alterations. Black participants had significant enrichment for MYC (8q) and PIK3CA (3q26) amplifications and higher total aneuploidy, but age was not associated with copy number variation. SES was associated with different patterns of alteration in Black versus non-Black women. Overall, Black participants showed modest differences in TP53, PIK3CA, and other alterations that further varied by SES. Race is a social construct, and varying distributions of etiologic factors across social strata may predispose Black, young, and low SES women to cancer subtypes characterized by these alterations. Significance: The collection and analysis of DNA sequencing with comprehensive socioeconomic factor associations in a large Black breast cancer patient cohort could help uncover mechanisms by which social conditions contribute to tumor biology.

Year:

2025

Year:

2025

The ternary complex of progesterone receptor membrane component 1 (PGRMC1)–sigma-2 receptor/transmembrane protein 97 (σ2R/TMEM97)–low-density lipoprotein receptor (LDLR) has recently been discovered and plays a role in cholesterol transport. This study investigated whether individual components of that complex are prognostic breast cancer biomarkers and have defined expression in established molecular subtypes. A total of 4,463 invasive breast cancers were analyzed as a function of molecular and phenotypic markers, estimates of cellular proliferation, and recurrence-free survival. A gene expression signature–based assay was utilized to estimate cellular proliferation. Cox proportional hazards regression estimated relapse-free survival and multivariate Cox analysis adjusted for the association of proliferation with early relapse. PGRMC1–σ2R/TMEM97–LDLR expression was stratified by immunohistochemical (IHC) and molecular subtype, tumor grade, and size. TMEM97 exhibited the strongest correlation with proliferation, highest in estrogen receptor (ER)–positive disease (r = 0.59, P = 8.1−114). TMEM97 and PGRMC1 were associated with a risk of early recurrence, dependent upon their association with proliferation. The risk of early recurrence was highest with TMEM97 and only seen in ER+/HER2− disease [HR = 1.5; 95% confidence interval (CI) = 1.35–1.67; P = 5.4−14] and ER+ malignancies (HR = 1.49; 95% CI = 1.31–1.68; P = 3.1−10). There was no increased risk of recurrence with TMEM97 expression in ER−/HER2− (HR = 1.05; 95% CI = 0.88–1.25; P = 0.63) or ER− disease (HR = 1.02; 95% CI = 0.89–1.17; P = 0.75). Components of a ternary complex associated with rapid internalization of low-density lipoprotein are biomarkers associated with cellular proliferation and early recurrence, which should help guide studies exploring them in the context of additional markers of aggressive disease. Elucidating the role of PGRMC1, TMEM97, and LDLR in breast cancer will facilitate a mechanistic understanding of how proliferation interplays with cholesterol metabolism in malignant transformation or propagation. Significance: This first large-scale analysis of the putative ternary complex responsible for rapid low-density lipoprotein internalization in breast cancer reveals a link between component expression and recurrence, with prognostic implications for identifying patients needing supplemental posttreatment surveillance and/or additional therapeutic approaches.

Year:

2025

Etiological heterogeneity occurs when distinct sets of events or exposures give rise to different subtypes of disease. Inference about subtype-specific exposure effects from two-phase outcome-dependent sampling data requires adjustment for both confounding and the sampling design. Common approaches to inference for these effects do not necessarily adjust appropriately for these sources of bias, or allow for formal comparisons of effects across different subtypes. We show that using inverse probability weighting (IPW) to fit a multinomial model to yield valid inference with this sampling design for subtype-specific exposure effects, and contrasts thereof. We compare the IPW approach to common regression-based methods for assessing exposure effect heterogeneity using simulations. The methods are applied to estimate subtype-specific effects of various exposures on breast cancer risk in the Carolina Breast Cancer Study (1993-2001).

Year:

2025

Background: Understanding the change in emotional well-being (EWB) and functional well-being (FWB) in breast cancer survivors can facilitate targeted support for unmet needs. Methods: Among 2,767 women with breast cancer in the Carolina Breast Cancer Study Phase 3, we assessed EWB and FWB with the Functional Assessment of Cancer Therapy – Breast instrument at 5 (baseline), 25, and 84 months after diagnosis. We identified well-being trajectories using latent class growth analysis, and relative frequency differences (RFD) with 95% confidence intervals (CI) were estimated for associations between trajectory group membership and demographic or clinical characteristics. Results: Five trajectory groups were identified for both EWB and FWB. Most participants (∼70%) were classified into “good well-being” (“stable high” or “stable medium”). A small percentage (∼10%) fell into “very low baseline” or “early decrease”, and the rest were “stable low” (∼20%). Overall, younger vs. older age was associated with “stable low” EWB (25.4% vs. 19.3%; RFD 6.1%; 95% CI, 3.0%–9.2%). Black participants more frequently had “stable low” FWB (24.2% vs. 16.6%; RFD 7.6%; 95% CI, 4.6%–10.6%). Breast cancer recurrence was strongly associated with “stable low” EWB (28.7% vs. 21.3%; RFD 7.3%; 95% CI, 2.3%–12.3%) and FWB (28.7% vs. 19.2%; RFD 8.6%; 95% CI, 3.7%–13.5%). Being unmarried, lower income, having nonprivate insurance, advanced stage, mastectomy vs. breast conservation surgery, and chemotherapy were also predictors of poor well-being trajectories. Conclusions: Demographics and clinical features are associated with sustained poor well-being after breast cancer. Impact: Improvements in long-term well-being may warrant targeted support.

Year:

2025

Background: Immunotherapy is a rapidly evolving treatment option in breast cancer; However, the breast cancer immune microenvironment is understudied in Black and younger ( Methods: We used histologic and RNA-based immunoprofiling methods to characterize the breast cancer immune landscape in 1,952 tumors from the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black ( n = 1,030) and young women ( n = 1,039). We evaluated immune response leveraging markers for 10 immune cell populations, compared profiles to those in The Cancer Genome Atlas (TCGA) Project [ n = 1,095 tumors, Black ( n = 183), and young women ( n = 295)], and evaluated in association with clinical and demographic variables, including recurrence. Results: Consensus clustering identified three immune clusters in CBCS (adaptive-enriched, innate-enriched, or immune-quiet) that varied in frequency by race, age, tumor grade and subtype; however, only two clusters were identified in TCGA, which were predominantly comprised of adaptive-enriched and innate-enriched tumors. In CBCS, the strongest adaptive immune response was observed for basal-like, HER2-positive (HER2 + ), triple-negative breast cancer (TNBC), and high-grade tumors. Younger patients had higher proportions of adaptive-enriched tumors, particularly among estrogen receptor (ER)-negative (ER − ) cases. Black patients had higher frequencies of both adaptive-enriched and innate-enriched tumors. Immune clusters were associated with recurrence among ER − tumors, with adaptive-enriched showing the best and innate-enriched showing the poorest 5-year recurrence-free survival. Conclusions: These data suggest that immune microenvironments are intricately related to race, age, tumor subtype, and grade. Impact: Given higher mortality among Black and young women, more defined immune classification using cell-type–specific panels could help explain higher recurrence and ultimately lead to targetable interventions.

Year:

2025

Background: Obese women have higher risk of aggressive breast tumors and distant metastasis. However, obesity has rarely been assessed in association with metastasis in diverse populations. Methods: In the Carolina Breast Cancer Study Phase 3 (2008–2013), waist-to-hip ratio (WHR), body mass index (BMI), and molecular subtype [PAM50 risk-of-recurrence (ROR) score] were assessed. Obesity measures were evaluated in association with metastasis within five years of diagnosis, overall and stratified by race and ROR score. Absolute risk of metastasis and risk differences between strata were calculated using the Kaplan–Meier estimator, adjusted for age, grade, stage, race, and ER status. Relative frequency of metastatic site and multiplicity were estimated in association with obesity using generalized linear models. Results: High-WHR was associated with higher risk of metastasis (5-year risk difference, RD, 4.3%; 95% confidence interval, 2.2–6.5). It was also associated with multiple metastases and metastases at all sites except brain. The 5-year risk of metastasis differed by race (11.2% and 6.9% in Black and non-Black, respectively) and ROR score (19.5% vs. 6.6% in high vs. low-to-intermediate ROR-PT). Non-Black women and those with low-to-intermediate ROR scores had similar risk in high- and low-WHR strata. However, among Black women and those with high ROR, risk of metastasis was elevated among high-WHR (RD Black/non-Black = 4.6%, RD High/Low-Int = 3.1%). Patterns of metastasis were similar by BMI. Conclusions: WHR is associated with metastatic risk, particularly among Black women and those with high-risk tumors. Impact: Understanding how risk factors for metastasis interact may help in tailoring care plans and surveillance among patients with breast cancer.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (76)

Katherine Hoadley

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Paul Delamater

Assistant Professor

University of North Carolina

UNITED STATES
View details

Montserrat Garcia-Closas

Professor of Epidemiology

Institute of Cancer Research

UNITED KINGDOM
View details

Di Wu

Associate Professor

University of North Carolina

UNITED STATES
View details

Sandra Hayes

Professor, Senior Research Fellow, Group lead

Griffith University

AUSTRALIA
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Andriy Derkach

Associate Attending Biostatistician

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Jennifer Hu

Professor

University of Miami

UNITED STATES
View details

Melissa LaBonte

Senior Lecturer

The Queen's University Belfast

UNITED KINGDOM
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Shreya Raghavan

Associate Professor

Texas A&M University

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Shiv Prakash Verma

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mya Roberson

University of North Carolina at Chapel Hill

UNITED STATES
View details

Stephanie Craig

The Queen's University Belfast

UNITED KINGDOM
View details

Charles Perou

Professor

University of North Carolina

UNITED STATES
View details

Laura Kennedy

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES
View details

Lanshan Huang

Queen's University Belfast

UNITED KINGDOM
View details

Stefan Ambs

Senior Investigator (tenured) and Head of the Molecular Epidemiology Section

National Cancer Institute

UNITED STATES
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

suneil jain

Queen's University Belfast

UNITED KINGDOM
View details

Sara E Wobker

University of North Carolina at Chapel Hill

UNITED STATES
View details

Kevin Williams

Professor

North Carolina Central University

UNITED STATES
View details

Robert Mach

Britton Chance Professor

University of Pennsylvania

UNITED STATES
View details

Terry Hyslop

Professor, Director of SKCCC Center for Cancer Health Equity

Thomas Jefferson University

UNITED STATES
View details

Wei Zheng

-

UNITED STATES
View details

Lisa Anne Carey

Deputy Director for Clinical Science

University of North Carolina at Chapel Hill

UNITED STATES
View details

Yara G Abdou

University of North Carolina at Chapel Hill

UNITED STATES
View details

Parag Katira

Professor

San Diego State University

UNITED STATES
View details

Andrew B. Smitherman

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

David A. Mankoff

Matthew J Wilson Professor and Research Vice-Chair of Radiology

University of Pennsylvania

UNITED STATES
View details

Stephen Chanock

National Institutes of Health

UNITED STATES
View details

Qiuyin Cai

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Katherine Reeder-Hayes

Professor with Tenure

University of North Carolina at Chapel Hill

UNITED STATES
View details

Amber Wilcox

Staff Scientist

Division of Cancer Epidemiology and Genetics, National Cancer Institute

UNITED STATES
View details

Mia Gaudet

Senior Scientist of the Connect for Cancer Prevention Study

National Cancer Institute

UNITED STATES
View details

Benjamin Calhoun

Associate Professor

University of North Carolina

UNITED STATES
View details

Xiaopeng Sun

Vanderbilt University

UNITED STATES
View details

Xiaohong Yang

National Cancer Institute

UNITED STATES
View details

GUOCHONG JIA

Vanderbilt University

UNITED STATES
View details

Andrew Olshan

University of North Carolina at Chapel Hill

UNITED STATES
View details

Sonya Reid

Vanderbilt University Medical Center

UNITED STATES
View details

Chris Baggett

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Charles F. Lynch

-

UNITED STATES
View details

Caroline Thompson

Associate Professor

University of North Carolina at Chapel Hill Gillings School of Global Public Health

UNITED STATES
View details

Michael Love

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Dezheng Huo

University of Chicago

UNITED STATES
View details

Gordon Watt

Junior Group Leader

The Netherlands Cancer Institute

NETHERLANDS
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Xingyi Guo

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Sarah Van Alsten

University of North Carolina at Chapel Hill

UNITED STATES
View details

Stephanie Downs-Canner

University of North Carolina at Chapel Hill

UNITED STATES
View details

Jirong Long

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Stephen D. Hursting

University of North Carolina

UNITED STATES
View details

Nicole Velmeshev

Assistant Professor

North Carolina Central University

UNITED STATES
View details

Jennifer Elston Lafata

University of North Carolina

UNITED STATES
View details

Didong Li

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Melanie Plinsinga

Griffith University

AUSTRALIA
View details

Stephanie B. Wheeler

University of North Carolina at Chapel Hill

UNITED STATES
View details

Hazel B Nichols

Professor

University of North Carolina at Chapel Hill Gillings School of Global Public Health

UNITED STATES
View details

Andrew Kossenkov

Assistant Professor

The Wistar Institute

UNITED STATES
View details

Yaohua Yang

Assistant Professor

University of Virginia

UNITED STATES
View details

Stephen Finn

Associate Professor

Trinity College Dublin School of Medicine

IRELAND
View details

Adam Pfefferle

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Jian Gu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Olufunmilayo I. Olopade

Professor

University of Chicago

UNITED STATES
View details

Lewis Chodosh

Professor and Chairman

University of Pennsylvania

UNITED STATES
View details

Svasti Haricharan

Associate Professor

San Diego State University

UNITED STATES
View details

Christopher Li

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Angela Stover

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Elizabeth McDonald

University of Pennsylvania

UNITED STATES
View details

Xiaohua Gao

University of North Carolina

UNITED STATES
View details